Follow
Chenyu Lin
Title
Cited by
Cited by
Year
Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools
L Gerratana, AA Davis, M Polano, Q Zhang, AN Shah, C Lin, D Basile, ...
European Journal of Cancer 143, 147-157, 2021
392021
Engineering alternate cooperative-communications in the lactose repressor protein scaffold
S Meyer, R Ramot, K Kishore Inampudi, B Luo, C Lin, S Amere, CJ Wilson
Protein Engineering, Design & Selection 26 (6), 433-443, 2013
282013
BiTE‐Secreting CAR‐γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors
SW Huang, CM Pan, YC Lin, MC Chen, Y Chen, CI Jan, CC Wu, FY Lin, ...
Advanced Science 10 (17), 2206856, 2023
132023
Emerging role of genomics and cell-free DNA in breast cancer
L Gerratana, AA Davis, AN Shah, C Lin, C Corvaja, M Cristofanilli
Current treatment options in oncology 20, 1-15, 2019
132019
Macrophage-derived IL-1β regulates emergency myelopoiesis via the NF-κB and C/ebpβ in Zebrafish
Z Wei, C Li, Y Zhang, C Lin, Y Zhang, L Shu, L Luo, J Zhuo, L Li
The Journal of Immunology 205 (10), 2694-2706, 2020
112020
Long-term antithrombotic therapy after venous stent placement
C Lin, KA Martin, M Wang, BL Stein, KR Desai
Phlebology 35 (6), 402-408, 2020
102020
Multicenter long-term follow-up of allogeneic hematopoietic cell transplantation with omidubicel: A pooled analysis of five prospective clinical trials
C Lin, A Schwarzbach, J Sanz, P Montesinos, P Stiff, S Parikh, ...
Transplantation and Cellular Therapy 29 (5), 338. e1-338. e6, 2023
92023
Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer
AN Shah, KJ Carroll, L Gerratana, C Lin, AA Davis, Q Zhang, S Jacob, ...
Breast Cancer Research and Treatment 187 (2), 397-405, 2021
92021
A phase i trial of SYK inhibition with fostamatinib in the prevention and treatment of chronic graft-Versus-Host disease
C Lin, RA DiCioccio, T Haykal, WC McManigle, Z Li, SM Anand, JC Poe, ...
Transplantation and Cellular Therapy 29 (3), 179. e1-179. e10, 2023
72023
Health-related quality of life following allogeneic hematopoietic cell transplantation with omidubicel versus umbilical cord blood
C Lin, G Sajeev, PJ Stiff, CG Brunstein, C Cutler, G Sanz, CA Lindemans, ...
Transplantation and cellular therapy 29 (1), 52. e1-52. e9, 2023
72023
Phase II study of single-agent and combination everolimus and panobinostat in relapsed or refractory diffuse large B-cell lymphoma
P Islam, D Rizzieri, C Lin, C de Castro, L Diehl, Z Li, J Moore, T Morris, ...
Cancer Investigation 39 (10), 871-879, 2021
72021
Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.
G Roloff, R Faramand, I Aldoss, NE Kopmar, M Schwartz, SE Dekker, ...
Journal of Clinical Oncology 41 (16_suppl), 7001-7001, 2023
52023
Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell ALL: Outcomes and Novel Insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)
GW Roloff, I Aldoss, NE Kopmar, C Lin, SE Dekker, VK Gupta, ...
Blood 142, 1030, 2023
12023
CT-314 Multicenter Long-Term Follow Up of Allogeneic Hematopoietic Stem Cell Transplantation With Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials
C Lin, A Schwarzbach, P Montesinos, P Stiff, C Cutler, S Parikh, ...
Clinical Lymphoma Myeloma and Leukemia 22, S442, 2022
12022
Allogeneic stem cell transplantation with omidubicel: long-term follow-up from a single center
C Lin, L Morrison, EP Alyea III, T Choi, C Gasparetto, GD Long, RD Lopez, ...
Blood 138, 1827, 2021
12021
Long-term antithrombotic therapy after venous stent placement
C Lin, KA Martin, M Wang, BL Stein, KR Desai
Blood 132, 1249, 2018
12018
The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
TE O'Connor, C Lin, G Roloff, A Zhang, I Aldoss, RG Faramand, ...
Transplantation and Cellular Therapy 30 (2), S326, 2024
2024
Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World …
C Lin, SB Tsai, G Roloff, A Zhang, I Aldoss, NE Kopmar, SE Dekker, ...
Transplantation and Cellular Therapy, Official Publication of the American …, 2024
2024
Efficacy of Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Toxicities–a Multicenter Retrospective Analysis
A Bajwa, Q Zhao, MJ Geer, A Mian, C Lin, D Frame, J Westholder, ...
Transplantation and Cellular Therapy, Official Publication of the American …, 2024
2024
Toxicity Profile of Brexucabtagene Autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Patients (pts) with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic …
NE Kopmar, T Gooley, GW Roloff, I Aldoss, C Lin, SE Dekker, VK Gupta, ...
Blood 142, 522, 2023
2023
The system can't perform the operation now. Try again later.
Articles 1–20